Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma
(MedPage Today) -- Data presented at the 2023 American Society of Hematology (ASH) annual meeting demonstrated that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2024 Category: Hematology Source Type: news
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL
(MedPage Today) -- Initial treatment with lenalidomide (Revlimid), tafasitamab (Monjuvi), rituximab, and acalabrutinib (Calquence) led to complete responses (CRs) in 64% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 27, 2023 Category: Hematology Source Type: news
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma?
(MedPage Today) -- Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients receiving treatment with the Janus... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 21, 2023 Category: Hematology Source Type: news
No Benefit to Salvage Transplant in R/R Multiple Myeloma No Benefit to Salvage Transplant in R/R Multiple Myeloma
Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Time to Stop Routine Maintenance Therapy in Myeloma? Time to Stop Routine Maintenance Therapy in Myeloma?
Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Roche to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders
Basel, 2 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will be presenting more than 45 abstracts at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, spanning 10 haematology indications.New data reflect Roche ’s commitment to advancing treatment standards even further to help improve the lives of people with blood disorders. This includes new areas, as well as diseases where its medicines have already changed the standard of care, such as haemophilia A, diffuse large B-cell lymphoma (DLBCL) and follicu lar lymphoma (FL). These data also support Roche’s mission to dev...
Source: Roche Investor Update - November 2, 2023 Category: Pharmaceuticals Source Type: news
Cediranib Shows Promise for Differentiated Thyroid Cancer
TUESDAY, Sept. 19, 2023 -- The multitargeted tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) pathway, cediranib, shows promise for differentiated thyroid cancer (DTC), but the addition of lenalidomide to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 19, 2023 Category: Pharmaceuticals Source Type: news
Bristol Myers banks on 25-plus label expansions to help weather IRA, Revlimid generics and more
With the potential for more than two dozen label expansions on the horizon, Bristol Myers Squibb bets its pipeline can help it withstand the pressure from the Inflation Reduction Act and a trio of | With the potential for more than two dozen label expansions on the horizon, Bristol Myers Squibb…#bristolmyerssquibb (Source: Reuters: Health)
Source: Reuters: Health - September 16, 2023 Category: Consumer Health News Source Type: news
FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Media News - June 27, 2023 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Investor Update - June 16, 2023 Category: Pharmaceuticals Source Type: news
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
THURSDAY, June 8, 2023 -- For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online June 5 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 8, 2023 Category: Pharmaceuticals Source Type: news
CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma
The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
